Abstract: A transport packaging includes a tray formation which is configured to hold a plurality of containers with mutual separation to avoid mutual contact of the containers. The tray formation includes a first tray part having a plurality of pockets configured to receive first ends of the containers and a second tray part removably coupled to the first tray part and having a corresponding plurality of pockets configured to receive second ends of the containers. The first tray part is formed such that, when the second tray part is removed so that the second ends of the containers are free from the pockets of the second tray part, the free second ends of the containers are free to be brought into mutual contact while the first ends of the containers are still received in the pockets of the first tray part.

Abstract: A transport packaging includes a tray formation which is configured to hold a plurality of containers with mutual separation to avoid mutual contact of the containers. The tray formation includes a first tray part having a plurality of pockets configured to receive first ends of the containers and a second tray part removably coupled to the first tray part and having a corresponding plurality of pockets configured to receive second ends of the containers. The first tray part is formed such that, when the second tray part is removed so that the second ends of the containers are free from the pockets of the second tray part, the free second ends of the containers are free to be brought into mutual contact while the first ends of the containers are still received in the pockets of the first tray part.

Abstract: A method for manufacturing a stationary state of polymer crystallinity of an active substance charged polylactide matrix for a stent, comprising the steps of: preparing the active substance charged polylactide matrix containing (a) a polylactide in amorphous or semicrystalline modification or with amorphous domains, and (b) at least one active substance on a surface or in a cavity of the stent communicating with the surface; and heating of the active substance charged polylactide matrix to a temperature ranging from TG-20° C. to TS-10° C., where TG represents a glass transition temperature and TS a melting temperature of the crystallites of the polylactide.

Abstract: An implant having a preferably hollow cylindrical main structure comprising a large number of continuous openings and a coating which releases at least one pharmaceutically active substance. To attain a better distribution of the pharmaceutically active substance, at least 20% of the cross-sectional area, preferably at least 50% of the cross-sectional area, of at least a portion of the openings in a predetermined section of the main structure is covered with the coating which releases at least one pharmaceutically active substance. Furthermore, a system composed of a catheter and such an implant, a simple method for manufacturing such an implant or such a system is provided.

Abstract: An agent depot for mechanical connection to a surface of an endovascular implantable body, comprising one or more polymers, one or more bioactive agents, the agent depot being mechanically connectable to the implantable body by a force fit or an adhesive.

Abstract: A stent comprising a degradable metal stent main body; a partition layer which is applied to the surface of the stent main body so that at least parts of the surface of the luminal side are not covered; and an agent-containing layer which is applied to the surface of the partition layer at least partially on the abluminal side of the stent main body and comprises one or more agents and possibly one or more polymers.

Abstract: An implant having a preferably hollow cylindrical main structure comprising a large number of continuous openings and a coating which releases at least one pharmaceutically active substance. To attain a better distribution of the pharmaceutically active substance, at least 20% of the cross-sectional area, preferably at least 50% of the cross-sectional area, of at least a portion of the openings in a predetermined section of the main structure is covered with the coating which releases at least one pharmaceutically active substance. Furthermore, a system composed of a catheter and such an implant, a simple method for manufacturing such an implant or such a system is provided.

Abstract: The present invention relates to a catheter comprising a balloon (10, 30) and at least one pharmaceutically active substance. To enable more accurate dosing of the pharmaceutically active substance, the pharmaceutically active substance is disposed in a reservoir (15, 35) inside the balloon (10, 30) or on the balloon (10, 30), wherein a wall (14, 32, 34) that closes the reservoir toward the outside comprises at least one predetermined breaking point (16). Furthermore, a system for applying an intraluminal endoprosthesis, preferably a stent, in a body cavity, and simple and cost-effective methods for manufacturing the catheter and the system are described.

Abstract: An agent depot for mechanical connection to a surface of an endovascular implantable body, comprising one or more polymers, one or more bioactive agents, the agent depot being mechanically connectable to the implantable body by a force fit or an adhesive.

Abstract: A method for producing an agent depot for mechanical connection to a surface of an endovascular implantable body, comprising a) providing one or more polymers; b) providing one or more agents; and c) producing an agent depot from said polymers and said agents, the agent depot being mechanically connectable to the surface of the body using force action or adhesive.

Abstract: The invention relates to a drug-loaded implant having a carrier body (10) and at least one drug for delivery into a delivery region. The drug is provided for chemotherapy and/or palliative treatment and can be released topically and/or regionally in a controlled manner at a predefinable rate and/or over a predefinable period of time in the intended active state of the implant.

Abstract: A stent comprising a degradable metal stent main body; a partition layer which is applied to the surface of the stent main body so that at least parts of the surface of the luminal side are not covered; and an agent-containing layer which is applied to the surface of the partition layer at least partially on the abluminal side of the stent main body and comprises one or more agents and possibly one or more polymers.

Abstract: A method for producing an agent depot for mechanical connection to a surface of an endovascular implantable body, comprising a) providing one or more polymers; b) providing one or more agents; and c) producing an agent depot from said polymers and said agents, the agent depot being mechanically connectable to the surface of the body using force action or adhesive.

Abstract: The invention concerns an endovascular implant, in particular a stent, with an at least portion-wise active coating. The object of the present invention is to provide locally therapeutic formulations for the treatment of stenosis or restenosis. The implants modified in accordance with the invention are to ensure improved compatibility, in particular in regard to any inflammatory and proliferative processes in the tissue environment. That is achieved in that the active coating includes, as an active substance: 1) PPAR?-agonists, PPAR?-agonists or a combination thereof; 2) an RXR-agonist; or 3) a combination of PPAR-agonists and RXR-agonists.

Abstract: A method for producing a composite made of oligonucleotides or polynucleotides and hydrophobic biodegradable polymers. The method comprises the following steps: (i) producing an aqueous solution of a polyethylene glycol having a mean molecular weight in the range from 600 to 8,000 g/mole; (ii) adding an aqueous, possibly buffered solution of oligonucleotides or polynucleotides to the aqueous solution from step (i); iii) freezing the aqueous solution from step (ii) and subsequently freeze-drying the frozen solution to obtain a freeze-dried substrate; (iv) providing a solution of the hydrophobic biodegradable polymer in an organic solvent; (v) adding the substrate obtained according to step (iii) to the solution of the polymer; and (vi) removing the organic solvent to obtain the composite. Also disclosed is a composite produced by the method.

Abstract: A method for manufacturing a stationary state of polymer crystallinity of an active substance charged polylactide matrix for a stent, comprising the steps of: preparing the active substance charged polylactide matrix containing (a) a polylactide in amorphous or semicrystalline modification or with amorphous domains, and (b) at least one active substance on a surface or in a cavity of the stent communicating with the surface; and beating of the active substance charged polylactide matrix to a temperature ranging from TG?20° C. to TS?10° C., where TG represents a glass transition temperature and TS a melting temperature of the crystallites of the polylactide.

Abstract: The invention concerns an endovascular implant, in particular a stent, with an at least portion-wise active coating. The object of the present invention is to provide locally therapeutic formulations for the treatment of stenosis or restenosis. The implants modified in accordance with the invention are to ensure improved compatibility, in particular in regard to any inflammatory and proliferative processes in the tissue environment. That is achieved in that the active coating includes, as an active substance: 1) PPAR&agr;-agonists, PPAR&dgr;-agonists or a combination thereof; 2) an RXR-agonist; or 3) a combination of PPAR-agonists and RXR-agonists.